COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report

Yi-Feng Wu; Wan-Jun Yu; Yu-Hua Jiang; Yin Chen; Bo Zhang; Rui-Bing Zhen; Jun-Tao Zhang; Yi-Ping Wang; Qiang Li; Feng Xu; Yan-Jun Shi; Xian-Peng Li

doi:10.12998/wjcc.v9.i19.5266

COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report

World J Clin Cases. 2021 Jul 6;9(19):5266-5269. doi: 10.12998/wjcc.v9.i19.5266.

Authors

Yi-Feng Wu¹, Wan-Jun Yu², Yu-Hua Jiang³, Yin Chen³, Bo Zhang³, Rui-Bing Zhen², Jun-Tao Zhang⁴, Yi-Ping Wang⁵, Qiang Li⁶, Feng Xu⁷, Yan-Jun Shi⁸, Xian-Peng Li⁹

Affiliations

¹ Department of Hepatobiliary and Pancreas Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
² Department of Respiratory Disease and Critical Care Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
³ Department of Infectious Diseases, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
⁴ Department of Ophthalmology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
⁵ Department of Laboratory Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
⁶ Department of Radiology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
⁷ Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
⁸ Department of Hepatobiliary and Pancreas Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 315009, Zhejiang Province, China.
⁹ Department of Infectious Diseases, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China. rmlixianpeng@nbu.edu.cn.

Abstract

Background: Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported.

Case summary: A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d.

Conclusion: COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.

Keywords: COVID-19; Case report; Diagnose; Hepatitis B virus; Reactivation; Therapy.

Publication types

Case Reports